Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

交易中 09-29 11:33:45 EDT

11.51

+0.09

+0.79%

最高11.67	最低11.42	成交量121.96万
今开11.49	昨收11.42	日振幅2.20%
总市值16.11亿	流通市值15.83亿	总股本1.40亿
成交额1,407万	换手率0.89%	流通股本1.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":11.51,"timestamp":1790696023244,"preClose":11.42,"halted":0,"volume":1219596,"delay":0,"changeRate":0.007880910683012247,"floatShares":137564483,"shares":140000000,"eps":-3.345616,"marketStatus":"交易中","change":0.09,"latestTime":"09-29 11:33:45 EDT","open":11.49,"high":11.67,"low":11.419,"amount":14065357.968395999,"amplitude":0.021979,"askPrice":11.52,"askSize":431,"bidPrice":11.51,"bidSize":325,"shortable":3,"etf":0,"ttmEps":-3.345616,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790712000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":11.42,"preHourTrading":{"tag":"盘前","latestPrice":11.43,"preClose":11.42,"latestTime":"09:29 EDT","volume":10395,"amount":120490.08741000001,"timestamp":1790688541018,"change":0.01,"changeRate":0.000876,"amplitude":0.038161},"postHourTrading":{"tag":"盘后","latestPrice":11.52,"preClose":11.42,"latestTime":"19:53 EDT","volume":346554,"amount":3958920.0487,"timestamp":1790639618165,"change":0.1,"changeRate":0.008757,"amplitude":0.028021},"volumeRatio":0.956161,"impliedVol":0.7858,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/NTLA/wiki","defaultTab":"wiki","newsList":[{"id":"2666251448","title":"数据：ARK Invest 旗下多只 ETF 同步买入 NTLA 与 Solana 质押 ETF，并减持 SLMT","url":"https://stock-news.laohu8.com/highlight/detail?id=2666251448","media":"链捕手","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666251448?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:18","pubTimestamp":1789085926,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Ark Invest Tracker 监测，ARK Invest 于 2026 年 9 月 10 日对旗下多只 ETF 进行了以下调仓操作：买入方向：ARKK、ARKG 同步买入 Intellia Therapeutics（NTLA），合计买入 89,284 股，分别占各基金总仓位的 0.0149% 和 0.0041%；ARKW、ARKF 同步买入 3IQ Solana Staking ETF（SOLQ.U），合计买入 4,021 股，分别占各基金总仓位的 0.001% 和 0.0019%。卖出方向：ARKK、ARKW、ARKF 同步减持 Brera Holdings PLC（SLMT），合计卖出 4,156 股，占比均不超过 0.0003%。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2289015","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOLX","ARKQ","ARKK","BK4544","SOL.USD.CC","SSK","SARK","BK4082","SOLM","SOL.USD.HKCC","BK4108","LU1861558580.USD","LU1861559042.SGD","FSOL","BK4550","BK4585","SLON","BK4535","BK4588","SLMT","FDN","SOLC","ARKX","QSOL","SOEZ","GSOL","BK4139","ARKF","SOLZ","BK4556","SOLT","ARKG","HSDT","BSOL","NTLA","TSOL","SSS","ARKW","VSOL","BK4600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108544920","title":"FDA优先审评Intellia罕见肿胀病疗法 盘前股价应声上涨4.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108544920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108544920?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869895,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已同意对Intellia Therapeutics公司一款治疗罕见肿胀疾病的药物进行快速通道审评。受此利好消息提振，该公司股价在盘前交易时段攀升4.9%。\n这一进展标志着Intellia Therapeutics在推进其创新疗法方面迈出了关键一步。获得FDA快速通道资格意味着该药物有望加速上市进程，为饱受罕见病困扰的患者带来新的治疗曙光。\n市场对这一消息反应积极，投资者普遍看好该疗法的商业化前景。分析人士指出，快速通道认定通常意味着监管机构认可该药物在解决未满足医疗需求方面具有显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4556","BK4535","LU1861558580.USD","BK4588","BK4139","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147894927","title":"Intellia Therapeutics获美国FDA受理Lonvo-Z生物制剂许可申请，并获优先审评资格，PDUFA日期定为2027年3月10日","url":"https://stock-news.laohu8.com/highlight/detail?id=1147894927","media":"美股速递","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147894927?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:06","pubTimestamp":1788869169,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已正式受理其Lonvo-Z的生物制剂许可申请（BLA），同时授予该申请优先审评资格。根据相关规定，FDA的《处方药用户付费法案》（PDUFA）目标行动日期设定为2027年3月10日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861558580.USD","BK4585","BK4588","NTLA","LU1861559042.SGD","BK4535","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172716505","title":"Intellia Therapeutics宣布FDA优先审查其遗传性血管性水肿（HAE）治疗药物Lonvoguran Ziclumeran（Lonvo-Z）生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1172716505","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172716505?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868876,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日宣布，美国食品药品监督管理局已正式受理其针对遗传性血管性水肿的候选药物Lonvoguran Ziclumeran所提交的生物制品许可申请，并授予优先审评资格。Intellia Therapeutics公司高层在声明中强调，这一进展不仅对公司研发管线意义重大，更体现了其致力于运用基因编辑技术变革遗传性疾病治疗范式的坚定承诺。FDA的此项决定，也再次印证了Lonvo-Z在前期临床试验中所展现出的巨大潜力及其尚未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861558580.USD","NTLA","BK4556","LU1861559042.SGD","BK4139","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174139552","title":"Intellia Therapeutics：五年合作期内，经双方协商一致，可额外获得1亿美元资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1174139552","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174139552?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:56","pubTimestamp":1788526590,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日宣布，在为期五年的合作期限内，若双方达成共识，公司将有权获取一笔额外的1亿美元资金。此项安排为公司的财务规划提供了更大的灵活性与战略空间。值得注意的是，这笔资金的释放并非自动生效，而是需要合作各方在具体条款上达成一致意见。通过这一机制，Intellia能够在保持稳健发展的同时，根据实际需求动态调整资金使用策略，从而更好地支持其研发管线布局与长期创新目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4556","BK4535","LU1861558580.USD","BK4588","BK4139","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104790109","title":"异动解读｜Intellia Therapeutics盘中下跌9.74%，报12.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104790109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104790109?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:50","pubTimestamp":1783968601,"startTime":"0","endTime":"0","summary":"7月14日，Intellia Therapeutics盘中下跌9.74%，报12.83美元/股，成交额6898.69万美元。Intellia Therapeutics所在的生物科技行业中，个股中，艾吉纳斯公司涨90.9%，Q32 Bio Inc.涨77.25%，艾伯维公司跌0.36%，阿尔尼拉姆制药公司跌4.22%，Moderna, Inc.跌1.96%。Intellia Therapeutics是一家基因编辑公司，专注于利用CRISPR/Cas9系统开发潜在治愈性疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819136","title":"基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819136","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645819136?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:21","pubTimestamp":1782310862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美股基因编辑概念普升，截至发稿，安捷伦科技 (A) 涨 4.21%，Beam Therapeutics (BEAM) 涨 3.55%，Intellia Therapeutics (NTLA) 涨 2.95%，Editas Medicine (EDIT) 涨 2.17%，福泰制药 (VRTX) 涨 1.28%。消息面上，建银国际新近研究认为，美国FDA近期发布了基因编辑疗法审评新规，允许药企在提供充分科学可比性论证的前提下，引用“先验知识”或既往成熟研究数据以加速研发，此举这标志着基因编辑疗法审评思路的重要转变，直接利好拥有相关技术平台的企业。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301875","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BEAM","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BN0W2V16.EUR","LU0234570918.USD","LU2362540622.SGD","A","LU0889565916.HKD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2324357040.USD","LU2089279066.USD","SG9999013999.USD","LU2413666699.HKD","LU2362541273.HKD","BK4588","IE00BJJMRZ35.SGD","LU0079474960.USD","LU1861559042.SGD","LU2092937221.SGD","VRTX","IE00BN0W2W23.USD","BK4139","BK4533","IE00B19Z9Z06.USD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","SGXZ57979304.SGD","LABU","IE00B894F039.SGD","LU1035775433.USD","BK4121","LU2041044095.USD","IE00BJT1NW94.SGD","LU1585245621.USD","EDIT","LU0256863811.USD","LU0432979614.USD","BK4611","BK4567","LU0320765992.SGD","NTLA","LU2229751404.USD","LU1861558580.USD","SG9999001176.SGD","IE00B19Z3581.USD","BK4505","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123375802","title":"Intellia Therapeutics旗下Haleo研究达到主要终点，Lonvo-Z组平均月发作次数降低87% (P<0.0001)","url":"https://stock-news.laohu8.com/highlight/detail?id=1123375802","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123375802?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:37","pubTimestamp":1781350635,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics宣布，其Haleo研究成功达到主要终点。数据显示，在Lonvo-Z治疗组中，患者平均每月发作次数实现了高达87%的显著降低，且该结果具有高度统计学意义（P值小于0.0001）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4556","BK4535","LU1861558580.USD","BK4588","BK4139","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122255214","title":"Intellia Therapeutics启动Lonvo-Z滚动BLA提交，预计2027年上半年在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1122255214","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122255214?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:33","pubTimestamp":1781350398,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics已正式启动其基因编辑疗法Lonvo-Z向美国食品药品监督管理局（FDA）的滚动生物制品许可申请（BLA）提交程序。这一关键步骤标志着该疗法向商业化迈出了重要一步。公司预计，若后续审查顺利，Lonvo-Z有望于2027年上半年在美国市场正式推出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4556","BK4535","LU1861558580.USD","BK4588","BK4139","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170241565","title":"Intellia Therapeutics公布Lonvoguran Ziclumeran (Lonvo-Z)治疗遗传性血管性水肿的3期试验更多积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170241565","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170241565?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:31","pubTimestamp":1781350278,"startTime":"0","endTime":"0","summary":"生物技术公司Intellia Therapeutics Inc公布了其候选疗法Lonvoguran Ziclumeran（研发代号Lonvo-Z）在治疗遗传性血管性水肿患者中的最新3期临床试验数据，结果显示出持续的积极疗效与安全性。\n此次公布的数据进一步巩固了该疗法在关键后期研究中的表现，为后续的监管申请提供了有力支持。遗传性血管性水肿是一种罕见的遗传性疾病，患者会反复出现皮下或黏膜下组织的严重肿胀，目前仍存在未满足的临床需求。\n公司表示，这些额外的积极结果增强了他们对Lonvo-Z潜力的信心，并计划持续推进相关开发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4556","LU1861559042.SGD","BK4139","BK4535","BK4588","BK4585","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146733927","title":"异动解读｜Intellia Therapeutics盘中上涨8.01%，报13.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146733927","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146733927?lang=zh_cn&edition=full","pubTime":"2026-05-28 03:35","pubTimestamp":1779910518,"startTime":"0","endTime":"0","summary":"5月28日，Intellia Therapeutics盘中上涨8.01%，报13.62美元/股，成交额7197.21万美元。Intellia Therapeutics所在的生物科技行业中，个股中，再生元制药公司跌0.43%，艾伯维公司涨1.12%，安进涨0.47%，福泰制药涨0.71%，吉利德科学涨0.04%。Intellia Therapeutics是一家领先的基因编辑公司，专注于利用CRISPR/Cas9系统生物工具开发潜在治愈性疗法，致力于通过单一疗程永久编辑疾病相关基因，发展新一代治疗产品。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102451903","title":"异动解读 | Intellia Therapeutics盘中大跌8.12%，一季度营收下滑与生物科技板块疲软成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1102451903","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102451903?lang=zh_cn&edition=full","pubTime":"2026-05-19 00:07","pubTimestamp":1779120469,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics（NTLA）今日盘中股价大幅下挫，跌幅达8.12%，引发了市场关注。消息面上，此次下跌主要受到两方面因素影响。首先，公司此前公布的一季度业绩显示营收承压，一季度营收同比下降约9.6%，这加重了市场对于这家尚未有商业化产品的基因编辑公司其现金消耗速度以及研发管线推进节奏的担忧。其次，生物科技板块今日整体延续弱势，板块情绪疲软进一步放大了个股的跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190806195","title":"异动解读 | Intellia Therapeutics盘中大跌8.33%，一季度营收下滑及板块情绪疲软拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190806195","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190806195?lang=zh_cn&edition=full","pubTime":"2026-05-15 03:37","pubTimestamp":1778787472,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics（股票代码：NTLA）今日盘中股价大跌8.33%，引起了市场的广泛关注。消息面上，公司近日公布的第一季度业绩报告显示，其营收表现承压。尽管每股净亏损优于市场预期且同比收窄，但一季度营收为1504.8万美元，较去年同期下降约9.6%。对于尚未有商业化产品的生物科技公司而言，营收下滑的信号加重了市场对其现金消耗及研发管线推进节奏的担忧。此外，同日内生物科技板块整体情绪偏弱，同行业公司股价亦出现显著下跌，进一步放大了Intellia Therapeutics的个股跌幅。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161536536","title":"异动解读 | Intellia Therapeutics因1.8亿美元股票出售盘前大跌9.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161536536","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161536536?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:54","pubTimestamp":1777463676,"startTime":"0","endTime":"0","summary":"基因编辑公司Intellia Therapeutics Inc今日盘前股价大跌9.25%，引发了市场关注。消息面上，此次股价下跌主要与公司宣布的一项融资活动有关。Intellia Therapeutics公布了1.8亿美元的后续发行定价，计划发行约1,670万股，发行价为每股10.75美元，这一价格较其前一交易日的收盘价有显著折让，幅度达到18.6%。此类股权融资通常会增加市场流通股数量，并对现有股价产生稀释压力，从而导致股价在短期内承压下跌。高盛、花旗集团和杰富瑞担任此次发行的联合簿记管理人。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170978288","title":"异动解读 | 券商上调目标价，Intellia Therapeutics盘中大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170978288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170978288?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:09","pubTimestamp":1777385355,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，多家券商发布了针对该公司的研究报告并上调了其目标价。其中，Canaccord Genuity将目标价从48美元上调至58美元，Leerink Partners将目标价从29美元上调至35美元。作为一家专注于基因编辑疗法的生物技术公司，Intellia Therapeutics的市场表现一直受到分析师和投资者的密切关注。此次券商集体上调目标价，进一步强化了市场对其长期发展潜力的看好。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158550621","title":"异动解读 | Intellia Therapeutics宣布增发1.5亿美元股票叠加市场预期失准，夜盘大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550621","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158550621?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:25","pubTimestamp":1777335940,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日夜盘股价大跌5.06%，引起了市场的广泛关注。消息面上，该公司宣布将启动一项承销式公开增发计划，拟出售总值1.5亿美元的普通股。此举通常会稀释现有股东的权益，是导致股价承压的直接原因之一。分析指出，鉴于该疗法是一次性高成本疗法，市场对其要求很高，股市反应反映了市场预期失准，这进一步加剧了股价的下跌压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145034547","title":"Intellia Therapeutics宣布拟公开增发普通股 募资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145034547","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145034547?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:02","pubTimestamp":1777320160,"startTime":"0","endTime":"0","summary":"生物制药领域先驱Intellia Therapeutics近日宣布，将启动一项承销式公开增发计划，拟出售总值1.5亿美元的普通股。本次增发的全部股份均由Intellia公司直接售出。本次普通股发行依据Intellia此前向美国证券交易委员会提交的S-3ASR格式自动生效注册声明进行。Intellia Therapeutics作为临床阶段的生物制药领军企业，始终致力于通过CRISPR基因编辑技术颠覆传统医疗模式。公告信息截至发布当日，公司无法律义务不主动更新内容。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","BK4535","BK4556","LU1861559042.SGD","LU1861558580.USD","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160253672","title":"异动解读 | Intellia Therapeutics基因疗法试验结果积极但市场预期失准，股价盘中大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160253672","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160253672?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:12","pubTimestamp":1777317168,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘中股价大跌5.06%，引起了市场的关注。消息面上，该公司今日早间公布了其实验性基因编辑疗法Lonvoguran Ziclumeran针对遗传性血管水肿的3期临床试验积极结果。尽管数据积极，但分析师指出，鉴于Lonvo-Z是一次性高成本疗法，市场对其要求很高，股市反应平淡反映了市场预期失准。试验中观察到的副作用均为轻度或中度，未出现严重不良事件。Intellia预计将于2026年下半年完成该疗法的美国监管申报，若获批准，可能于2027年上半年在美国上市。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125743996","title":"Intellia Therapeutics疗法达成试验主要目标 早盘股价飙升8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125743996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125743996?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:37","pubTimestamp":1777289844,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc（NTLA）股价在盘前交易中大幅跃升8%，此前该公司宣布其针对罕见遗传病的实验性疗法在临床试验中达到了主要研究目标。\n这一积极数据提振了投资者对这家生物技术公司基因编辑平台潜力的信心。该疗法旨在通过精准的基因编辑技术治疗特定罕见遗传疾病，其临床试验结果标志着公司在该领域取得重要进展。\n市场对该消息反应强烈，股价的显著上涨反映出投资者对Intellia Therapeutics技术前景的乐观态度。基因编辑领域近年来备受关注，此次试验成功可能为该公司未来发展和潜在商业化奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4139","NTLA","BK4588","BK4585","BK4556","LU1861558580.USD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188005880","title":"Intellia Therapeutics Inc公布Lonvo-Z三期Haelo试验达成主要及所有关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1188005880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188005880?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:12","pubTimestamp":1777288358,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc宣布，其候选疗法Lonvo-Z的三期Haelo临床试验成功达到主要研究终点以及全部关键次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LU1861559042.SGD","LU1861558580.USD","BK4585","BK4588","BK4139","NTLA","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":-0.0655},{"period":"1month","weight":-0.1127},{"period":"3month","weight":-0.3251},{"period":"6month","weight":-0.1394},{"period":"1year","weight":-0.2998},{"period":"ytd","weight":0.2703}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.046678},{"month":2,"riseRate":0.7,"avgChangeRate":0.065016},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068585},{"month":4,"riseRate":0.5,"avgChangeRate":-0.029374},{"month":5,"riseRate":0.3,"avgChangeRate":0.006419},{"month":6,"riseRate":0.909091,"avgChangeRate":0.227192},{"month":7,"riseRate":0.545455,"avgChangeRate":0.006651},{"month":8,"riseRate":0.545455,"avgChangeRate":0.036595},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.019192},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105594},{"month":11,"riseRate":0.6,"avgChangeRate":0.07833},{"month":12,"riseRate":0.3,"avgChangeRate":-0.083863}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况